Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. (REVB) is a clinical-stage biotechnology company pioneering immunologic therapeutics through its proprietary Gemini platform. This centralized news hub provides investors and healthcare professionals with essential updates on the company's inflammatory disease research and clinical developments.
Access timely reports on Revelation Biosciences' therapeutic pipeline including Gemini-SSI (surgical infection prevention), Gemini-AKI (acute kidney injury), and Gemini-CKD (chronic kidney disease) programs. Our curated news collection covers clinical trial milestones, regulatory updates, scientific presentations, and strategic partnerships relevant to TLR4 agonist development.
This resource serves investors tracking the company's progress in inflammation modulation and researchers monitoring PHAD-based therapeutic innovations. Content is rigorously verified to ensure accurate reporting on Revelation Biosciences' clinical-stage developments without speculative commentary.
Bookmark this page for streamlined access to REVB's latest press releases, peer-reviewed study findings, and material event disclosures. Check regularly for updates on the Gemini formulation's advancement through clinical testing phases and related biopharmaceutical industry developments.
Revelation Biosciences (NASDAQ:REVB) submitted and had its end-of-phase 1 meeting package accepted by the FDA, and is on track to hold the meeting later in 2025 to get agency feedback on the regulatory pathway for Gemini as a treatment for acute kidney injury (AKI).
The company reported that its Phase 1b PRIME study in stage 3–4 chronic kidney disease met its primary safety and tolerability endpoint and showed reductions in inflammatory activity and restored cellular responses in PBMCs up to 168 hours post-dose. Revelation plans to initiate a later-stage clinical study in 2026 and to publish additional PRIME results while exploring other indications for Gemini.
Revelation Biosciences (NASDAQ:REVB) reported results for the three and nine months ended September 30, 2025, and disclosed corporate and cash updates.
Key points: the company announced top-line PRIME clinical study results, received $9.6 million gross from a September 2025 warrant inducement, and held $12.7 million cash as of September 30, 2025 (up from $6.5 million at December 31, 2024).
Operating highlights include $6.3 million net cash used in operating activities for the nine months ended September 30, 2025 (down from $14.6 million in 2024), a Q3 2025 net loss of $1.9 million (loss per share $(1.77)), and a nine‑month net loss of $6.4 million (loss per share $(9.76)). The company expects cash to fund operations through Q3 2026 and plans to meet with the FDA to align on Gemini’s registration path.
Revelation Biosciences (NASDAQ:REVB) announced the cancellation of the adjourned Special Meeting of Stockholders that had been rescheduled for October 29, 2025 due to a technical difficulty that prevented stockholders from voting all of their shares.
The company set a new record date of October 29, 2025 and scheduled a new Special Meeting for December 3, 2025. Revelation will mail new proxy materials to all stockholders of record as of the new record date and urges stockholders to vote promptly upon receipt.
Revelation Biosciences (NASDAQ:REVB) announced that its 2025 Special Meeting of Stockholders originally convened on October 15, 2025 was adjourned due to insufficient shares present and will reconvene on October 29, 2025 at 12:00 p.m. ET.
The meeting remains virtual via webcast and the record date of September 11, 2025 is unchanged. Stockholders who already voted need not act unless they wish to change their vote; those who have not voted are encouraged to vote before the new meeting date by following the instructions in the proxy materials.
Additional meeting and voting details are available in the company's proxy statement filed with the SEC.
Revelation Biosciences (NASDAQ:REVB) has announced a significant warrant exercise agreement that will generate $9.6 million in gross proceeds. The agreement involves the immediate exercise of 4,355,000 outstanding warrants at $2.20 per share, originally issued on May 29, 2025.
As part of the transaction, exercising holders will receive new Class I warrants to purchase up to 13,065,000 shares of common stock in a private placement. These new warrants will be exercisable at $2.20 per share for five years after stockholder approval. The company will file a resale registration statement within 20 days of closing to register the shares underlying the new warrants.
Revelation Biosciences (NASDAQ:REVB) announced groundbreaking results from its Phase 1b PRIME clinical study of Gemini in stage 3 and 4 chronic kidney disease (CKD) patients. The study met its primary safety endpoint and demonstrated significant efficacy in normalizing inflammatory response at the cellular level.
The trial enrolled 40 patients across 3 US clinics, divided into 5 cohorts. Key findings showed Gemini significantly reduced inflammation in patients with high background PBMC activity and corrected immunoparalysis typical to chronic disease. The drug was well-tolerated at the target dose, with mostly mild adverse events reported.
The company plans an End of Phase 1 meeting with the FDA later this year to discuss program advancement. The results suggest potential breakthrough applications for treating both acute and chronic inflammatory conditions.
Revelation Biosciences (NASDAQ:REVB) has issued a reminder for their upcoming webcast and conference call scheduled for September 10th at 8:30 am Eastern Time. The event will discuss top-line data from their PRIME Phase 1b clinical trial.
Participants can join via webcast or dial in using the toll-free number 888-506-0062 (US) or +1 973-528-0011 (International) with access code 289672. The company has made available both the original data announcement and the presentation materials on their website.
Revelation Biosciences (NASDAQ:REVB) announced positive top-line results from its Phase 1b PRIME clinical study of Gemini in stage 3 and 4 chronic kidney disease (CKD) patients. The study met its primary safety endpoint and demonstrated significant efficacy in normalizing inflammatory responses at the cellular level.
The study enrolled 40 patients across 3 US clinics, with 5 cohorts testing different dose levels. Notably, Gemini showed remarkable ability to reduce inflammation in patients with high background PBMC activity and correct immunoparalysis typical to chronic disease. The effects remained significant through 7 days after a single dose.
The treatment was well-tolerated at the target dose, with mostly mild adverse events. The company plans to discuss advancing the program with the FDA at an upcoming End of Phase 1 meeting.
Revelation Biosciences (NASDAQ: REVB) reported its financial results for Q2 2025, highlighting key operational and financial developments. The company completed patient dosing in the PRIME Phase 1b Clinical Study of Gemini in CKD patients and secured $4 million in gross proceeds from a public offering in May 2025.
Financial position shows $5.2 million in cash and cash equivalents as of June 30, 2025, down from $6.5 million at year-end 2024. The Q2 2025 net loss improved to $2.4 million ($(7.01) per share), compared to $8.4 million ($(246.27) per share) in Q2 2024. Current cash runway is expected to fund operations through December 2025.
Revelation Biosciences (NASDAQ:REVB) announced that its former chairman and shareholder, Dr. George Tidmarsh, has been appointed to head the FDA Center for Drug Evaluation and Research. Dr. Tidmarsh, who serves as an Adjunct Professor at Stanford University School of Medicine, has over three decades of biotech innovation experience and has successfully guided multiple medications through FDA approval.
Additionally, the company recently completed dosing in its PRIME Phase 1b clinical study of Gemini, investigating escalating doses administered intravenously in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).
FAQ
What is the current stock price of Revelation Biosciences (REVB)?
What is the market cap of Revelation Biosciences (REVB)?
